Daiichi Sankyo and Merck’s BLA for ifinatamab deruxtecan granted priority review in US for adult patients with ES-SCLC who experienced disease progression on or after platinum-based chemotherapy ...
Daiichi Sankyo (TSE: 4568) and Merck’s, known as MSD outside of the United States and Canada, (NYSE: MRK) Biologics License Application (BLA) for ifinatamab deruxtecan (I-DXd) has been accepted and ...
A new study co-led by the Institute for Systems Biology (ISB) shows that some lung cancers can change identity as they evolve ...
A new approach using lipid nanoparticles to deliver genetic material is showing promise in tackling two major challenges in ...
Sirolimus and Cyclosporine With Post-Transplant Cyclophosphamide or Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Hematopoietic Cell Transplantation Eligible ...
A new review highlights how lactylation—a lactate-induced protein modification—drives lung cancer progression, immune escape, and therapy resistance. It details the “writer-eraser-reader” regulatory ...
LEXINGTON, Mass., Feb. 20, 2026 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) announced findings from a post hoc analysis of the eNRGy trial (NCT02912949) evaluating treatment beyond progression ...
Spatial maps of lung precancer and cancer cells at different points in development advance understanding of the earliest stages of lung cancer Findings highlight inflammation as a driver of lung tumor ...
As the nation recognizes Women’s History Month, Illinois health leaders have launched a renewed, statewide effort to increase awareness of lung cancer screening among Black and Hispanic adults ages 50 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results